ArticleOncotarget2018
Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR.
Shencun Fang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papercites it
ArticleOncotarget2018
Shencun Fang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.